Corporate Profile

Cortexyme, Inc. is a clinical stage biopharmaceutical company focused on rare and degenerative diseases. The company’s innovative pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others.

Recent Events

Investor Relations

News Releases

13 Jun '22
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 13, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray , a pharmaceutical industry veteran and global drug development and
20 May '22
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S.
20 May '22
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Featured Reports

More information is coming soon.